MedWatch

Octagon Therapeutics graduates from pilot project to research alliance with Novo Nordisk

After concluding a pilot under Novo Nordisk’s accelerator program, the US-based company is ready to take a bigger step with the Danish pharmaceutical giant.

Photo: Bernd Von Jutrczenka/AP/Ritzau Scanpix

Novo Nordisk and Octagon Therapeutics, a US-based biotech company, have joined forces under a research alliance, according to a press release from earlier in September.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs